Skip to main content

Table 1 Baseline characteristics of studied population according to gender

From: Screening premorbid metabolic syndrome in community pharmacies: a cross-sectional descriptive study

  Total n = 650 Men n = 313 Women n = 337 p
Age1 (years) 48.4 (SD = 12.5) 48.9 (SD = 12.5) 48.0 (SD = 12.5) 0.341
Waist C1 (cm) 92.3 (SD = 13.6) 97.7 (SD = 11.6) 87.1 (SD = 13.3) <0.001
BMI1 (kg/m2) 26.4(SD = 4.5) 27.1 (SD = 4.1) 25.7 (SD = 4.7) <0.001
Fasting glucose1 (mg/dl) 93.6 (SD = 14.6) 95.5 (SD = 14.6) 91.9 (SD = 14.3) 0.002
Total cholesterol1 (mg/dl) 204.9 (SD = 39.6) 201.8 (SD = 41.2) 207.8 (SD = 37.8) 0.051
HDL-cholesterol1 (mg/dl) 58.7 (SD = 14.7) 55.4 (SD = 13.4) 61.8 (SD = 15.3) <0.001
Triglyceride1 (mg/dl) 123.0 (SD = 83.4) 138.7 (SD = 102.6) 108.3 (SD = 56.5) <0.001
SBP1 (mm Hg) 127.2 (SD = 16.2) 130.5 (SD = 16.1) 124.2 (SD = 15.7) <0.001
DBP1 (mm Hg) 77.3 (SD = 10.5) 79.5 (SD = 10.2) 75.2 (SD = 10.3) <0.001
CVR1 (Score) 1.5 (SD = 1.9) 2.4 (SD = 2.1) 0.8 (SD = 1.1) <0.001
CVR1 (Regicor) 3.4 (SD = 2.3) 3.9 (SD = 2.6) 2.9 (SD = 1.9) <0.001
AC drugs2 30.0 (26.5-33.5) 33.5 (28.3-38.7) 26.7 (22.0-31.4) 0.060
AH drugs2 32.3 (28.7-35.9) 40.3 (34.9-45.7) 24.9 (20.3-29.5) <0.001
Smoking habit2 30.0 (26.5-33.5) 34.8 (29.5-40.1) 25.5 (20.8-30.2) 0.010
Physical inactivity2 58.5 (54.7-62.3) 52.7 (47.2-58.2) 63.8 (58.7-68.9) 0.005
  1. p ≤ 0.05 is considered to be statistically significant.
  2. 1Data are expressed as means (Standard Deviation).
  3. 2Data are expressed as percentages (95% confidence interval).
  4. Waist C waist circumference; BMI body mass index; SBP systolic blood pressure; DBP diastolic blood pressure; CVR cardiovascular risk; AC Drugs pharmacological treatment of hypercholesterolemia or hypertriglyceridemia; AH Drugs pharmacological treatment of hypertension.